3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
No longer available
1
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
2
Expanded_access
1
Sponsor
Cancer Type
CNS
3
Sarcoma
2
Conditions
Glioblastoma
3
Neoplasms
2
Gliosarcoma
2
Brain Neoplasms
2
Recurrence
1
Glioma
1
Interventions
Temozolomide
94
Radiotherapy
40
Bevacizumab
40
Lomustine
21
Radiation
18
Surgical Procedures, Operative
10
Carboplatin
9
pembrolizumab
8
Nivolumab
8
Carmustine
8
Irinotecan
7
IL13-PE38
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Flucytosine
6
Cyclophosphamide
6
ABT-414
6
vocimagene amiretrorepvec
5
depatuxizumab mafodotin
5
Valacyclovir
5
Drug Therapy
5
veledimex
4
sargramostim
4
enzastaurin
4
NVP-BKM120
4
Gemcitabine
4
Dianhydrogalactitol
4
Chlorotoxin
4
Aminolevulinic Acid
4
verubulin
3
selinexor
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Glioblastoma
×
rindopepimut
×
Clear all
NCT01498328
2020-02-17
ReACT
Celldex Therapeutics
Phase 2
Completed
127 enrolled
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled
NCT03068650
2017-10-18
CDX-110
Celldex Therapeutics
No longer available